Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 31 | 2025 | 340 | 10.650 |
Why?
|
| Influenza Vaccines | 20 | 2024 | 150 | 7.170 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 18 | 2024 | 83 | 5.180 |
Why?
|
| Vaccination | 14 | 2024 | 279 | 4.120 |
Why?
|
| Antibodies, Viral | 12 | 2024 | 311 | 3.260 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 9 | 2024 | 106 | 2.510 |
Why?
|
| Seasons | 10 | 2024 | 240 | 2.280 |
Why?
|
| Immunologic Memory | 5 | 2024 | 164 | 1.950 |
Why?
|
| Influenza A virus | 5 | 2025 | 172 | 1.940 |
Why?
|
| Vaccines | 5 | 2022 | 84 | 1.810 |
Why?
|
| Antigens, Viral | 9 | 2024 | 145 | 1.770 |
Why?
|
| Host-Pathogen Interactions | 8 | 2024 | 237 | 1.760 |
Why?
|
| Antigenic Variation | 6 | 2024 | 27 | 1.610 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 9 | 2024 | 72 | 1.610 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2018 | 117 | 1.550 |
Why?
|
| Antibodies, Neutralizing | 6 | 2024 | 123 | 1.540 |
Why?
|
| B-Lymphocytes | 6 | 2024 | 740 | 1.530 |
Why?
|
| Orthomyxoviridae | 7 | 2020 | 36 | 1.530 |
Why?
|
| Pneumococcal Infections | 4 | 2018 | 47 | 1.510 |
Why?
|
| Influenza B virus | 5 | 2025 | 32 | 1.510 |
Why?
|
| Communicable Diseases | 3 | 2023 | 63 | 1.450 |
Why?
|
| Streptococcus pneumoniae | 4 | 2018 | 49 | 1.410 |
Why?
|
| Evolution, Molecular | 7 | 2018 | 856 | 1.220 |
Why?
|
| Cross Protection | 3 | 2024 | 9 | 1.080 |
Why?
|
| Selection, Genetic | 4 | 2018 | 517 | 1.060 |
Why?
|
| Epidemics | 3 | 2023 | 34 | 1.000 |
Why?
|
| Models, Biological | 7 | 2020 | 1766 | 0.970 |
Why?
|
| Age Distribution | 2 | 2021 | 199 | 0.870 |
Why?
|
| Immunogenicity, Vaccine | 4 | 2021 | 13 | 0.860 |
Why?
|
| Humans | 63 | 2025 | 90014 | 0.850 |
Why?
|
| Biological Evolution | 5 | 2021 | 974 | 0.810 |
Why?
|
| Adaptive Immunity | 3 | 2015 | 167 | 0.810 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2020 | 13 | 0.800 |
Why?
|
| Disease Susceptibility | 4 | 2024 | 200 | 0.800 |
Why?
|
| Models, Theoretical | 4 | 2021 | 493 | 0.770 |
Why?
|
| Models, Immunological | 4 | 2018 | 81 | 0.750 |
Why?
|
| Off-Label Use | 1 | 2021 | 16 | 0.740 |
Why?
|
| Antibodies | 2 | 2023 | 353 | 0.720 |
Why?
|
| Child | 11 | 2025 | 7241 | 0.630 |
Why?
|
| Silent Mutation | 1 | 2018 | 3 | 0.610 |
Why?
|
| Child, Preschool | 7 | 2025 | 3773 | 0.610 |
Why?
|
| HIV | 1 | 2018 | 48 | 0.600 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 76 | 0.560 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.550 |
Why?
|
| Models, Statistical | 8 | 2022 | 576 | 0.550 |
Why?
|
| Humidity | 1 | 2017 | 91 | 0.550 |
Why?
|
| Carrier State | 2 | 2018 | 39 | 0.550 |
Why?
|
| Adaptation, Physiological | 3 | 2018 | 317 | 0.550 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 73 | 0.540 |
Why?
|
| Young Adult | 9 | 2025 | 6423 | 0.530 |
Why?
|
| Pandemics | 6 | 2022 | 778 | 0.520 |
Why?
|
| Antibody Diversity | 1 | 2015 | 25 | 0.510 |
Why?
|
| Adolescent | 9 | 2025 | 9352 | 0.500 |
Why?
|
| Immunodominant Epitopes | 2 | 2015 | 20 | 0.490 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.480 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 23 | 0.460 |
Why?
|
| Age Factors | 4 | 2024 | 1879 | 0.440 |
Why?
|
| Hong Kong | 3 | 2023 | 45 | 0.430 |
Why?
|
| Immune System | 1 | 2014 | 97 | 0.430 |
Why?
|
| Haemophilus Infections | 1 | 2012 | 7 | 0.420 |
Why?
|
| Haemophilus influenzae | 1 | 2012 | 15 | 0.420 |
Why?
|
| Adult | 14 | 2025 | 26845 | 0.420 |
Why?
|
| Incidence | 5 | 2020 | 1604 | 0.400 |
Why?
|
| Nasopharynx | 1 | 2012 | 50 | 0.390 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1221 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 800 | 0.390 |
Why?
|
| Infant | 5 | 2025 | 3189 | 0.380 |
Why?
|
| Computer Simulation | 6 | 2022 | 1102 | 0.380 |
Why?
|
| Antigens, Bacterial | 1 | 2012 | 136 | 0.380 |
Why?
|
| Aged | 11 | 2025 | 19269 | 0.370 |
Why?
|
| Animals | 14 | 2024 | 27551 | 0.370 |
Why?
|
| Host Specificity | 1 | 2010 | 13 | 0.350 |
Why?
|
| Eggs | 2 | 2021 | 12 | 0.350 |
Why?
|
| Middle Aged | 10 | 2025 | 26179 | 0.330 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 288 | 0.310 |
Why?
|
| RNA Viruses | 1 | 2008 | 10 | 0.310 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6784 | 0.300 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 491 | 0.300 |
Why?
|
| Virus Diseases | 1 | 2008 | 99 | 0.300 |
Why?
|
| Asymptomatic Infections | 2 | 2024 | 17 | 0.290 |
Why?
|
| Neutralization Tests | 2 | 2024 | 80 | 0.270 |
Why?
|
| Cross Reactions | 3 | 2018 | 109 | 0.260 |
Why?
|
| Pneumococcal Vaccines | 2 | 2018 | 28 | 0.260 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 26 | 0.240 |
Why?
|
| Family Characteristics | 1 | 2025 | 49 | 0.240 |
Why?
|
| Neuraminidase | 1 | 2024 | 46 | 0.240 |
Why?
|
| Basic Reproduction Number | 2 | 2022 | 6 | 0.230 |
Why?
|
| Coinfection | 1 | 2025 | 62 | 0.230 |
Why?
|
| Zoonoses | 2 | 2016 | 26 | 0.230 |
Why?
|
| Female | 9 | 2025 | 46620 | 0.220 |
Why?
|
| Male | 8 | 2025 | 42705 | 0.210 |
Why?
|
| Epitopes | 3 | 2021 | 254 | 0.210 |
Why?
|
| Algorithms | 3 | 2018 | 1912 | 0.210 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 51 | 0.210 |
Why?
|
| Germ Cells | 1 | 2023 | 130 | 0.210 |
Why?
|
| Cohort Studies | 2 | 2020 | 2886 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 53 | 0.200 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1729 | 0.190 |
Why?
|
| Amino Sugars | 1 | 2021 | 3 | 0.190 |
Why?
|
| Ferrets | 2 | 2018 | 48 | 0.190 |
Why?
|
| New Zealand | 1 | 2021 | 21 | 0.190 |
Why?
|
| Prevalence | 3 | 2020 | 1250 | 0.190 |
Why?
|
| Viral Load | 1 | 2022 | 145 | 0.190 |
Why?
|
| Mass Vaccination | 1 | 2021 | 9 | 0.190 |
Why?
|
| Health Priorities | 1 | 2021 | 22 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2021 | 35 | 0.180 |
Why?
|
| Polysaccharides | 1 | 2021 | 91 | 0.180 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2020 | 48 | 0.180 |
Why?
|
| Time Factors | 3 | 2019 | 5362 | 0.180 |
Why?
|
| Wisconsin | 1 | 2020 | 41 | 0.180 |
Why?
|
| Phylogeny | 3 | 2018 | 1198 | 0.180 |
Why?
|
| United States | 6 | 2024 | 7115 | 0.180 |
Why?
|
| Probability | 1 | 2021 | 351 | 0.180 |
Why?
|
| Immunity, Innate | 2 | 2015 | 434 | 0.170 |
Why?
|
| Models, Genetic | 2 | 2015 | 949 | 0.170 |
Why?
|
| Alleles | 1 | 2023 | 1138 | 0.170 |
Why?
|
| Microbial Interactions | 2 | 2024 | 11 | 0.170 |
Why?
|
| Hemagglutinins | 1 | 2019 | 19 | 0.160 |
Why?
|
| Vaccines, Inactivated | 1 | 2018 | 29 | 0.160 |
Why?
|
| Vaccination Coverage | 1 | 2018 | 6 | 0.160 |
Why?
|
| Computational Biology | 2 | 2020 | 551 | 0.160 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 338 | 0.160 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 66 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 841 | 0.150 |
Why?
|
| Plasma Cells | 1 | 2018 | 85 | 0.150 |
Why?
|
| Genome, Viral | 1 | 2018 | 82 | 0.150 |
Why?
|
| Sentinel Surveillance | 2 | 2022 | 23 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2017 | 46 | 0.140 |
Why?
|
| New York City | 1 | 2016 | 61 | 0.140 |
Why?
|
| Chicago | 2 | 2022 | 1434 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 594 | 0.140 |
Why?
|
| Phylogeography | 1 | 2016 | 43 | 0.130 |
Why?
|
| Genetic Variation | 3 | 2014 | 1380 | 0.130 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2015 | 8 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1869 | 0.130 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 37 | 0.130 |
Why?
|
| Antibody Affinity | 1 | 2015 | 38 | 0.130 |
Why?
|
| Temperature | 1 | 2017 | 409 | 0.130 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2015 | 34 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1081 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 979 | 0.120 |
Why?
|
| Germinal Center | 1 | 2015 | 55 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 264 | 0.120 |
Why?
|
| Species Specificity | 2 | 2012 | 685 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1158 | 0.110 |
Why?
|
| Genetics, Population | 1 | 2016 | 408 | 0.110 |
Why?
|
| Genetic Fitness | 1 | 2012 | 39 | 0.100 |
Why?
|
| Mutation | 3 | 2019 | 4169 | 0.100 |
Why?
|
| Serotyping | 1 | 2012 | 28 | 0.100 |
Why?
|
| Bacterial Capsules | 1 | 2012 | 29 | 0.100 |
Why?
|
| Mice | 2 | 2023 | 11869 | 0.100 |
Why?
|
| Population Dynamics | 1 | 2012 | 138 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3682 | 0.100 |
Why?
|
| Measles virus | 1 | 2011 | 14 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 54 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2010 | 67 | 0.090 |
Why?
|
| Stochastic Processes | 1 | 2010 | 77 | 0.090 |
Why?
|
| Emigration and Immigration | 1 | 2010 | 48 | 0.090 |
Why?
|
| Receptors, Virus | 1 | 2010 | 75 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2011 | 216 | 0.090 |
Why?
|
| Illinois | 2 | 2022 | 485 | 0.090 |
Why?
|
| Cats | 1 | 2010 | 305 | 0.090 |
Why?
|
| Phenotype | 2 | 2014 | 2458 | 0.080 |
Why?
|
| Chickens | 2 | 2021 | 212 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 1008 | 0.080 |
Why?
|
| Birds | 1 | 2010 | 166 | 0.080 |
Why?
|
| World Health Organization | 2 | 2021 | 108 | 0.070 |
Why?
|
| Epidemiological Monitoring | 2 | 2016 | 39 | 0.060 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 9 | 0.060 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2025 | 18 | 0.060 |
Why?
|
| Michigan | 1 | 2025 | 54 | 0.060 |
Why?
|
| Outpatients | 1 | 2022 | 101 | 0.050 |
Why?
|
| Computer Systems | 1 | 2022 | 79 | 0.050 |
Why?
|
| Biohazard Release | 1 | 2021 | 1 | 0.050 |
Why?
|
| Philadelphia | 1 | 2020 | 18 | 0.050 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2020 | 37 | 0.050 |
Why?
|
| China | 1 | 2021 | 235 | 0.040 |
Why?
|
| Forecasting | 2 | 2011 | 304 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 467 | 0.040 |
Why?
|
| Global Health | 2 | 2011 | 193 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 646 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 83 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 146 | 0.040 |
Why?
|
| Ovum | 1 | 2017 | 59 | 0.040 |
Why?
|
| Glycosylation | 1 | 2017 | 128 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 982 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 2495 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 469 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 888 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 4326 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2016 | 112 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1395 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3044 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1148 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 33 | 0.030 |
Why?
|
| Parvovirus, Canine | 1 | 2011 | 1 | 0.020 |
Why?
|
| Disease Vectors | 1 | 2011 | 5 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2011 | 11 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 2011 | 6 | 0.020 |
Why?
|
| Switzerland | 1 | 2011 | 17 | 0.020 |
Why?
|
| Measles | 1 | 2011 | 16 | 0.020 |
Why?
|
| Animals, Wild | 1 | 2011 | 41 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2011 | 21 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 706 | 0.020 |
Why?
|
| Geographic Information Systems | 1 | 2010 | 23 | 0.020 |
Why?
|
| Asia | 1 | 2010 | 102 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2011 | 302 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2327 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 9239 | 0.020 |
Why?
|
| Pedigree | 1 | 2010 | 969 | 0.020 |
Why?
|
| Immunity, Herd | 1 | 2006 | 2 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3024 | 0.020 |
Why?
|
| Point Mutation | 1 | 2006 | 246 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 156 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 825 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 1854 | 0.010 |
Why?
|